Skip to main content

Table 2 General characteristics of population

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

  Population
N = 99
Afatinib
N = 40
Erlotinib
N = 26
Gefitinib
N = 33
Gender
Women 73 (73.7%) 28 (70.0%) 22 (84.6%) 23 (69.7%)
Men 26 (26.3%) 12 (30.0%) 4 (15.4%) 10 (30.3%)
Age (years) 61.2 (14.0) 57.925 (14.5) 64.3 (12.8) 62.8 (14.0)
Stage IV NSCLC 83 (83.8) 33 (82.5) 22 (84.61) 28 (84.84)
Current or former smoker 22 (22.2%) 3 (11.5%) 4 (12.1%) 15 (15.2%)
Woodsmoke exposure 16 (16.2%) 4 (15.4%) 6 (18.2%) 16 (16.2%)
Karnofsky
50 2 (2.2%) 1 (2.6%) 1 (4.2%) 0 (0.0%)
60 3 (3.2%) 2 (5.3%) 0 (0.0%) 1 (3.2%)
70 12 (12.9%) 4 (10.5%) 4 (16.7%) 4 (12.9%)
80 33 (35.5%) 14 (36.8%) 7 (29.2%) 12 (38.7%)
90 38 (40.9%) 16 (42.1%) 12 (50%) 10 (32.3%)
100 5 (5.4%) 1 (2.6%) 0 (0.0%) 4 (12.9%)
Not Reported 6 2 2 2
ECOG
0 2 (2.2%) 0 (0.0%) 0 (0.0%) 2 (6.5%)
1 75 (81.5%) 34 (91.9%) 18 (75.0%) 23 (74.2%)
2 12 (13.0%) 2 (5.4%) 4 (16.7%) 6 (19.4%)
3 3 (3.3%) 1 (2.7%) 2 (8.3%) 0 (0.0%)
Not Reported 7 3 2 2
Diabetes Mellitus 17 (17.2%) 5 (12.5%) 5 (19.2%) 7 (21.2%)
Arterial hypertension 23 (23.2%) 8 (20.0%) 7 (26.9%) 8 (24.2%)
EGFR Mutation
▪ EGFR del 19 25 (25.3%) 12 (30.0%) 5 (19.2%) 8 (24.2%)
▪ EGFR L858R 67 (67.7%) 27 (67.5%) 16 (61.5%) 24 (72.7%)
Non-reported 7 (7.1% 1 (2.5%) 5 (19.2%) 1 (3.0%)